Previous close | 6.61 |
Open | 6.15 |
Bid | 5.00 |
Ask | 9.00 |
Strike | 7.50 |
Expiry date | 2024-05-17 |
Day's range | 6.15 - 6.15 |
Contract range | N/A |
Volume | |
Open interest | 24 |
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
Sophia Randolph, Chief Medical Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), sold 12,000 shares of the company on May 13, 2024.
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.